Proactive Investors - Run By Investors For Investors

Avalon GloboCare adds Cornell cellular therapy director to its advisory board

Yen-Michael Sheng Hsu is the founding director of the Laboratory for Advanced Cellular Therapy at Weill Cornell Medicine
Stethoscope on a keyboard
Hsu also leads the Laboratory for Advanced Cellular Engineering at New York-Presbyterian Hospital

Avalon GloboCare Corp (NASDAQ:AVCO), a cellular therapeutics company, has added a director from the medical school at Cornell to its scientific and clinical advisory board.

Yen-Michael Sheng Hsu is the founding director of the Laboratory for Advanced Cellular Therapy at Weill Cornell Medicine. While there, he oversaw the creation of a cGMP cellular therapy facility, the first of its kind.

Hsu also leads the Laboratory for Advanced Cellular Engineering at New York-Presbyterian Hospital. He holds leadership positions in the Foundation for the Accreditation of Cellular Therapy and AABB, two cellular therapy organizations.

READ: Avalon GloboCare expects to be added to Russell 3000 Index

“We are pleased to welcome Dr. Hsu to our Scientific and Clinical Advisory Board,” CEO David Jin said. “He has been an invaluable asset in our exosome-based clinical programs for liquid biopsy and regenerative therapeutics. He also brings a wealth of knowledge, experience and leadership in cellular therapy, and has an impressive track record in both translational and clinical research fields.”

Avalon is a Freehold, New Jersey-based CellTech bio-developer focused on advancing cellular therapeutics utilizing exosomes, vesicles that sit outside and operate between cells.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

View full AVCO profile View Profile

Avalon GloboCare Corp Timeline

Related Articles

Enzymes under a microscope
April 29 2019
The Florida company applies its proprietary C1 gene expression platform to speed up the development of biologic vaccines, drugs at flexible commercial scales
scientist at petrie dish
May 15 2019
Here we take a closer look at Midatech Pharma PLC (LON:MTPH)
Oncoprex
October 18 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use